108 related articles for article (PubMed ID: 7599121)
1. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
2. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
3. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
4. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
[TBL] [Abstract][Full Text] [Related]
5. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
Carlier E; Mabrouk K; Moulard M; Fajloun Z; Rochat H; De Waard M; Sabatier JM
J Pept Res; 2000 Dec; 56(6):427-37. PubMed ID: 11152302
[TBL] [Abstract][Full Text] [Related]
6. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
[TBL] [Abstract][Full Text] [Related]
7. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
Barbouche R; Fenouillet E; Papandréou MJ; Kiény MP; Sabatier JM
J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
[TBL] [Abstract][Full Text] [Related]
8. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.
Yahi N; Fantini J; Mabrouk K; Tamalet C; de Micco P; van Rietschoten J; Rochat H; Sabatier JM
J Virol; 1994 Sep; 68(9):5714-20. PubMed ID: 8057453
[TBL] [Abstract][Full Text] [Related]
9. SPC3, a nontoxic peptide inhibitor of HIV infection.
Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
[No Abstract] [Full Text] [Related]
10. Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.
de Mareuil J; Mabrouk K; Doria E; Moulard M; de Chasteigner S; Oughideni R; van Rietschoten J; Rochat H; De Waard M; Sabatier JM
Antiviral Res; 2002 Jun; 54(3):175-88. PubMed ID: 12062390
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and conformational studies of N-glycosylated analogues of the HIV-1 principal neutralizing determinant.
Laczkó I; Hollósi M; Urge L; Ugen KE; Weiner DB; Mantsch HH; Thurin J; Otvös L
Biochemistry; 1992 May; 31(17):4282-8. PubMed ID: 1567873
[TBL] [Abstract][Full Text] [Related]
12. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
Barbouche R; Miquelis R; Sabatier JM; Fenouillet E
J Pept Sci; 1998 Dec; 4(8):479-85. PubMed ID: 9927254
[TBL] [Abstract][Full Text] [Related]
13. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions.
Vranken WF; Budesinsky M; Martins JC; Fant F; Boulez K; Gras-Masse H; Borremans FA
Eur J Biochem; 1996 Feb; 236(1):100-8. PubMed ID: 8617252
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.
Andrianov AM; Veresov VG
J Biomol Struct Dyn; 2007 Jun; 24(6):597-608. PubMed ID: 17508782
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
16. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
Huisman JG; Carotenuto A; Labrijn AF; Papavoine CH; Laman JD; Schellekens MM; Koppelman MH; Hilbers CW
Biochemistry; 2000 Sep; 39(35):10866-76. PubMed ID: 10978173
[TBL] [Abstract][Full Text] [Related]
17. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Wild C; Oas T; McDanal C; Bolognesi D; Matthews T
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10537-41. PubMed ID: 1438243
[TBL] [Abstract][Full Text] [Related]
18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
19. HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages.
Benjouad A; Seddiki N; Ylisastigui L; Gluckman JC
AIDS Res Hum Retroviruses; 1997 Feb; 13(3):219-26. PubMed ID: 9115808
[TBL] [Abstract][Full Text] [Related]
20. NMR and circular dichroism studies on the conformation of a 44-mer peptide from a CD4-binding domain of human immunodeficiency virus envelope glycoprotein.
Chang DK; Chien WJ; Cheng SF; Chen ST
J Pept Res; 1997 May; 49(5):432-43. PubMed ID: 9211225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
